Overview

Data as of July 22, 2019 12:14 pm EDT

Press Releases

Summary Toggle Madrigal Pharmaceuticals Promotes Rebecca Taub, M.D., Chief Medical Officer and Executive Vice President of Research & Development, to Newly Created Position of President of Research & Development

July 11, 2019

-- Dr. Taub to present at the 5th Paris NASH Meeting to be held on July 11-12, 2019 -- CONSHOHOCKEN, Pa. , July 11, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today the promotion of Rebecca Taub , M.D., to the newly created positon of President of Research &
Summary Toggle Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors

July 02, 2019

CONSHOHOCKEN, Pa. , July 02, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Jim Daly has been appointed to the Company’s Board of Directors, as a Class I director, effective as of June 27 , 2019. “We are extremely pleased to have an executive with Jim’s
Summary Toggle Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences

June 04, 2019

CONSHOHOCKEN, Pa. , June 04, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals , Inc. (NASDAQ:MDGL) today announced that Paul Friedman , M.D., Chief Executive Officer of Madrigal, and Becky Taub , M.D., CMO and Executive VP, Research & Development of Madrigal will present at the following

Filing date	Form	Description	Filing Group	View
June 13, 2005	RW	Withdrawal of registration statement filed under the Securities Act	Other	0001047469-05-017134.rtf 0001047469-05-017134.xls 0001047469-05-017134.pdf
February 13, 2007	4	Statement of changes in beneficial ownership of securities	3,4,5	0001179110-07-003589.rtf 0001179110-07-003589.pdf
February 13, 2007	4	Statement of changes in beneficial ownership of securities	3,4,5	0001179110-07-003591.rtf 0001179110-07-003591.pdf